Table 2 Subgroup analysis of the prevalence of positive thyroid autoantibodies in patients with infertility
Subgroup title | No. of trails | No. of participants | I2(%) | Pooled prevalence of TAI (95%CI) | P for value |
|---|---|---|---|---|---|
Overall | 48 | 33,475 | 94.45 | 0.20(0.18 to 0.22) | Â |
Location | |||||
Europe | 22 | 16,798 | 90.63 | 0.18(0.15 to 0.20) | 0.131 |
America | 8 | 4954 | 84.89 | 0.18(0.15 to 0.21) | |
Asia and Africa | 18 | 11,723 | 94.93 | 0.22(0.18 to 0.26) | |
Year | |||||
≤ 2000 | 11 | 4638 | 69.36 | 0.21(0.18 to 0.24) | 0.002 |
2001–2010 | 8 | 5358 | 85.59 | 0.15(0.12 to 0.19) | |
2011–2020 | 24 | 21,533 | 92.81 | 0.18(0.16 to 0.20) | |
≥ 2021 | 5 | 1946 | 90.48 | 0.29(0.22 to 0.37) | |
Type of infertility treatment | |||||
ART | 39 | 26,297 | 94.05 | 0.20(0.18 to 0.22) | 0.668 |
Non-ART | 9 | 7768 | 91.81 | 0.18(0.14 to 0.23) | |
Thyroid function status | |||||
Euthyroid | 28 | 17,897 | 90.35 | 0.20(0.17 to 0.22) | 0.690 |
Non-only euthyroid | 20 | 15,578 | 96.65 | 0.19(0.15 to 0.23) | |